Evommune surged 70% after EVO301's Phase 2a data showed rapid, significant EASI reductions in moderate-to-severe atopic ...
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Pharm Exec’s 21st Annual Pipeline Report examines emerging drug development classes, treatment modalities, and expansion pursuits in five therapeutic settings ripe for next-gen innovation.
Neurocrine Biosciences, Inc. leverages a strong cash position and a neuropsychiatry pipeline to drive long-term commercial ...
New disease-modifying agents are being evaluated in the clinic that could change the course of treatment for Alzheimer’s disease patients. Regulated industries like pharmaceuticals, biotech, and ...
Operating at millimetRE-wave frequencies introduces a set of engineering challenges that extend far beyond traditional radio frequency testing ...
A miniaturized radar chip, developed by researchers at Science Tokyo, advances Integrated Sensing and Communication for Beyond 5G and 6G systems ...
LCGC International salutes Jack Henion and Bob W.J. Pirok, winners of the 19th annual LCGC Lifetime Achievement and Emerging ...
EDN announces this year’s winners of the Electronic Products Product of the Year Awards, selected by the editors.
As an innovative subtype of invasive brain-computer interfaces (BCIs), the Endovascular Brain-Computer Interface (EBCI) enables electrode delivery to target brain regions via endovascular intervention ...
News-Medical.Net on MSN
Which hair loss supplements actually work?
By Dr. Priyom Bose, Ph.D. A large network meta-analysis ranks popular supplements for hair loss and shows who benefits most, ...
BackgroundAlzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by progressive cognitive decline and memory impairment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results